Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- CFD Research Corporation
- Proposal award date
- 2024-09-20
- Contract end date
- 2026-08-31
- UEI
- V3KCP1HNFM33
- Solicitation number
- PA23-230
- Topic code
- R
Research abstract
Project Summary/Abstract: CFD Research Corporation has developed a novel microbiome-balancing wet wrap therapy for atopic dermatitis based on a natural compound with unique physicochemical and pharmacological activities. The compound has been found to have an interleukin-based immune modulatory effect that helps soothe the flare- up of eczema, and it is highly selective to the pathogen Staphylococcus aureus while being gentle to the skin microbiome, including beneficial bacteria such as Roseomonas mucosa and Corynebacterium tuberculostearicum. The compound was incorporated into cellulose-based fabrics such as rayon and cotton to create a controlled-release wet wrap/bandage which will be tested on mouse models of eczema. The technology has the potential become a standard of care for treating eczema patients and decrease or eliminate the use of steroid ointments in controlling atopic dermatitis in children and adult populations.
Technology keywords
Not reported
Research funding history
947 SBIR/STTR records share this UEI (1987–2026). Reported award amounts total $350,893,199. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Defense, National Aeronautics and Space Administration, Department of Health and Human Services, National Science Foundation, Department of Commerce, Department of Energy
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards